慢性阻塞性肺疾病中的非酒精性脂肪性肝病
该研究在慢阻肺患者中用经验证的无创检测(FibroMax:SteatoTest、NashTest、FibroTest)评估脂肪变、非酒精性脂肪性肝炎(NASH)与肝纤维化,并分析其与慢阻肺严重程度、合并症及循环炎症因子的关系。结果显示慢阻肺患者脂肪变、NASH、纤维化患病率分别为41.4%、36.9%、61.3%,且与性别、BMI、未治疗睡眠呼吸暂停及胰岛素抵抗相关。
要点
- 慢阻肺患者中脂肪变、NASH、纤维化患病率分别为41.4%、36.9%、61.3%。
- SteatoTest与FibroTest均与性别、BMI、未治疗睡眠呼吸暂停及胰岛素抵抗相关。
- 脂肪变患者TNF-α更高,NASH或多种肝损伤并存者瘦素升高。
核心结论
- NAFLD在慢阻肺中高度流行,可能参与心脏代谢合并症的发生。
研究设计与样本
- 研究采用经验证的无创检测评估慢阻肺患者的脂肪变、NASH与肝纤维化。
- 对患者进行慢阻肺合并症的客观评估,包括睡眠研究。
- 生物学检测包括完整血脂谱与炎症标志物。
主要发现
- 慢阻肺患者脂肪变、NASH、纤维化患病率分别为41.4%、36.9%、61.3%。
- 多因素分析中SteatoTest与FibroTest显著关联性别、BMI、未治疗睡眠呼吸暂停和胰岛素抵抗。
- SteatoTest还额外关联慢阻肺GOLD分期。
- 脂肪变患者肿瘤坏死因子-α水平更高。
- 校正年龄、性别和BMI后,NASH或多种肝损伤组合者瘦素水平升高。
临床怎么用
- 对慢阻肺患者应关注NAFLD及心脏代谢合并症,可考虑无创肝评估。
- 合并未治疗睡眠呼吸暂停与胰岛素抵抗者肝损伤风险信号更强。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) is independently linked to cardiometabolic morbidity and mortality. Low-grade inflammation, oxidative stress and ectopic fat, common features of chronic obstructive pulmonary disease (COPD), might contribute to the development of NAFLD.We aimed to investigate the prevalence of NAFLD and to evaluate the relationship between various types of liver damage and COPD severity, comorbidities and circulating inflammatory cytokines. Validated noninvasive tests (FibroMax: SteatoTest, NashTest and FibroTest) were used to assess steatosis, nonalcoholic steatohepatitis (NASH) and liver fibrosis. Patients underwent an objective assessment of COPD comorbidities, including sleep studies. Biological parameters included a complete lipid profile and inflammatory markers.In COPD patients the prevalence of steatosis, NASH and fibrosis were 41.4%, 36.9% and 61.3%, respectively. In multivariate analysis, SteatoTest and FibroTest were significantly associated with sex, body mass index (BMI), untreated sleep apnoea and insulin resistance, and, in addition, COPD Global Initiative for Chronic Obstructive Lung Disease stage for SteatoTest. Patients with steatosis had higher tumour necrosis factor-α levels and those with NASH or a combination of liver damage types had raised leptin levels after adjustment for age, sex and BMI.We concluded that NAFLD is highly prevalent in COPD and might contribute to cardiometabolic comorbidities.
引用
- Viglino D, Jullian-Desayes I, Minoves M, et al. Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. Eur Respir J. 2017. PMID: 28596431. doi:10.1183/13993003.01923-2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。